Last reviewed · How we verify
larotaxel (XRP9881)
larotaxel (XRP9881) is a Taxane Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Metastatic breast cancer.
Larotaxel is a taxane dimer that inhibits microtubule dynamics, thereby inducing apoptosis in cancer cells.
Larotaxel is a taxane dimer that inhibits microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Metastatic breast cancer.
At a glance
| Generic name | larotaxel (XRP9881) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Larotaxel works by binding to tubulin and inhibiting its polymerization into microtubules, which are essential for cell division. This leads to the accumulation of cells in the G2/M phase and ultimately induces apoptosis in cancer cells. The exact mechanism of action is similar to other taxanes, such as paclitaxel and docetaxel.
Approved indications
- Metastatic breast cancer
Common side effects
- Neutropenia
Key clinical trials
- Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen (PHASE3)
- Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer (PHASE1, PHASE2)
- Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer (PHASE2)
- Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (PHASE3)
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients (PHASE2)
- XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer (PHASE2)
- Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment (PHASE2)
- Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- larotaxel (XRP9881) CI brief — competitive landscape report
- larotaxel (XRP9881) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about larotaxel (XRP9881)
What is larotaxel (XRP9881)?
How does larotaxel (XRP9881) work?
What is larotaxel (XRP9881) used for?
Who makes larotaxel (XRP9881)?
What drug class is larotaxel (XRP9881) in?
What development phase is larotaxel (XRP9881) in?
What are the side effects of larotaxel (XRP9881)?
What does larotaxel (XRP9881) target?
Related
- Drug class: All Taxane drugs
- Target: All drugs targeting Microtubules
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Compare: larotaxel (XRP9881) vs similar drugs
- Pricing: larotaxel (XRP9881) cost, discount & access